Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
FDA launches new priority review voucher program for select biopharmas
gene editing
Biotech
Eli Lilly pays $1B upfront to buy gene editing partner Verve
Eli Lilly confirms its buyout of Verve after an M&A report by the Financial Times Monday.
James Waldron
Jun 17, 2025 4:35am
Gene editing leaders call for 10-year ban on heritable edits
May 28, 2025 7:00am
CRISPR Tx, Sirius pen collab with a focus on thrombotic disease
May 20, 2025 3:59am
Boy with rare disease 'thriving' after 1st custom gene therapy
May 15, 2025 1:00pm
Appeals court reignites row over CRISPR discovery
May 13, 2025 8:00am
CRISPR Tx sees 80% fall in LDL, triglycerides after in vivo edit
May 7, 2025 10:00am